文献速递贫血与红细胞疾病

Parsaclisib治疗原发性自身免疫性溶血性贫血:一项2期开放标签研究结果

Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.
PubMed 文献 · Am J Hematol · 2024-10-22

这项2期开放标签多中心研究纳入25例成人温抗体型、冷凝集素病或混合型自身免疫性溶血性贫血患者,每日口服parsaclisib 1.0或2.5 mg共12周后进入延伸期。第6-12周期间64%患者达到部分或完全血红蛋白缓解,温抗体型缓解率高于其他类型(75.0% vs 44.4%)。所有患者均发生治疗中出现的不良事件,最常见为腹泻(32.0%)和发热(28.0%)。

要点

  • 25例患者中16例(64%)在第6-12周达到部分或完全血红蛋白缓解。
  • 温抗体型AIHA缓解率75.0%,其他类型44.4%。
  • 52.0%患者在治疗第1周即观察到缓解。

核心结论

  • Parsaclisib耐受性良好,在第1周即带来血红蛋白缓解的显著改善,且缓解在延伸期持续。

研究设计与样本

  • 2期、开放标签、多中心研究,纳入25例成人温抗体型AIHA、冷凝集素病或混合型AIHA患者。
  • 患者每日口服parsaclisib 1.0或2.5 mg共12周,随后进入延伸期;允许因AIHA加重而增加剂量或因耐受性而降低剂量。
  • 主要疗效终点为第6-12周期间任何访视时达到完全缓解(血红蛋白≥12 g/dL)或部分缓解(血红蛋白10-12 g/dL或较基线升高≥2 g/dL)且非输血所致者的比例。

主要发现

  • 25例入组患者(中位年龄63岁)中,16例(64%)在第6-12周期间达到部分或完全血红蛋白缓解。
  • 52.0%的患者在第1周即观察到缓解,第6-12周期间进一步改善,延伸期缓解持续。
  • 温抗体型AIHA患者缓解率高于其他类型(75.0% vs 44.4%)。
  • 第6周和第12周观察到功能性慢性病治疗评估-疲乏量表评分的临床意义改善。
  • 所有患者均发生治疗中出现的不良事件,最常见为腹泻(32.0%)和发热(28.0%);≥3级治疗中出现的不良事件发生于13例(52.0%),考虑可能与治疗相关的不良事件发生于11例(44.0%)。

关键数值与推荐

  • 完全缓解定义为血红蛋白≥12 g/dL;部分缓解定义为血红蛋白10-12 g/dL或较基线升高≥2 g/dL。
  • 主要疗效终点评估时间为第6-12周期间任何访视,且缓解不能归因于输血。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoimmune hemolytic anemia (AIHA) is a group of acquired autoimmune disorders characterized by red blood cell hemolysis. In a phase 2, open-label, multicenter study, adults with warm AIHA, cold agglutinin disease, or mixed-type AIHA were administered once-daily 1.0 or 2.5 mg parsaclisib (selective phosphoinositide 3-kinase δ inhibitor) orally for 12 weeks, followed by an extension period. Dose increases (for AIHA worsening) or decreases (for tolerability) were permitted. Primary efficacy endpoint was the proportion of patients with complete (≥12 g/dL hemoglobin [Hgb]) or partial (10-12 g/dL Hgb or ≥2 g/dL increase from baseline) response at any visit during weeks 6-12 not attributable to transfusion. Among 25 enrolled patients (median age, 63 y), 16 (64%) achieved a partial or complete Hgb response during weeks 6-12. Responses were observed by week 1 in 52.0% of patients with incremental improvements during weeks 6-12 and sustained responses during the extension period. Responses were higher among patients with warm AIHA versus other types (75.0% vs. 44.4%). Clinically meaningful improvements in Functional Assessment of Chronic Illness Therapy-Fatigue scores were observed at weeks 6 and 12. All patients had treatment-emergent adverse events (TEAEs), most commonly diarrhea (32.0%) and pyrexia (28.0%). Grade ≥3 TEAEs occurred in 13 patients (52.0%). TEAEs considered possibly related to treatment occurred in 11 patients (44.0%). No dose reductions were required; six patients (24%) discontinued for a TEAE. In summary, parsaclisib was well tolerated and resulted in substantial improvements in Hgb response at week 1, with durable responses through the extension period. CLINICAL TRIAL REGISTRATION: This trial was registered at ClinicalTrials.gov (NCT03538041).

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Barcellini W, Pane F, Patriarca A, et al. Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study. Am J Hematol. 2024. PMID: 39435908. doi:10.1002/ajh.27493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。